Fig. 6From: Trastuzumab in patients with breast cancer and pre-existing left ventricular systolic dysfunctionEstimated marginal means of LVEF in HER-2 positive breast cancer patients following treatment with Trastuzumab in serial echocardiography. Echocardiography 1 to 8 were performed during 12 months of trastuzumab treatment, and echocardiography 9 was performed 6 months after completion of treatment. LVEF: left ventricular ejection fractionBack to article page